Mid Face Volume Deficit
Conditions
Brief summary
Mid-face volume loss is a factor affecting beauty that makes people feel uncomfortable about themselves. The purpose of this study is to evaluate the efficacy and safety of Hyaluronic Acid injection with the brand name Alcarisa®, manufactured by Espad Pharmed Co., for treatment of this condition. The intervention consisted of a single treatment session, injecting 2 to 4 cc of gel into the zygomaticomalar area, and, if deemed by the physician, into the anteromedial cheek and submalar areas on each side of the face. The patient underwent digital photography at the following time points: before injection, immediately after injection, and at 4, 12, and 24 weeks post-injection. The physician then used these photographs to evaluate the product's efficacy and safety based on predefined measurements. In addition, participant satisfaction was assessed at the same time intervals.
Interventions
DEVICEAlcarisa (hyaluronic acid filler)
A single injection of Alcarisa filler with a maximum dose of 2 to 4 cc , was administered in the zygomaticomalar area, and if deemed appropriate by the physician, also in the anteromedial cheek and submalar areas on each side of the face.
Sponsors
Espad Pharmed
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
before/after clinical trial
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Men and women aged 30 to 65 years * Individuals with moderate to significant mid-face volume loss (score 3 to 4) based on changes in MFVDS (in cases of asymmetry between the two sides of the face, the more severe side will be considered) * Ability to comply with visit schedules and study procedures * Signed the informed consent form and agreed to 6-month follow-up
Exclusion criteria
* History of Type I hypersensitivity reactions or anaphylaxis * Known allergy or sensitivity to any components of the filler, lidocaine, or to proteins from the HA-producing microorganisms (Streptococci) * History of hypertrophic or keloid scarring, or bleeding disorders in the injection area * Active inflammatory processes, infections, lesions (malignant or benign), or scars in the injection area * History of streptococcal diseases (such as recurrent sore throat or acute rheumatic fever) in the past 6 months * History of autoimmune/immunodeficiency diseases, or use of immunosuppressive drugs during the 6 months prior to or during the study * History of surgery or trauma in the injection area within the past 6 months * Use of antiplatelet drugs within 72 hours prior to treatment, or anticoagulants within 2 weeks prior to or during treatment * Use of drugs that reduce or inhibit hepatic metabolism (e.g., cimetidine, beta-blockers) due to the presence of lidocaine * Pregnancy, breastfeeding, or plans to become pregnant in the near future during the study * Undergoing or planning to undergo cosmetic treatments in the near future during the study, such as: 1. Botulinum toxin type A injections below the zygomatic arch during the 6 months prior to study entry 2. Previous injections of temporary dermal fillers (e.g., bovine collagen, hyaluronic acid) in the facial area within 1 year prior to study entry 3. Use of calcium hydroxyapatite, poly-L-lactic acid, or permanent fillers (e.g., silicone), or fat injections in the injection area at any time before or during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| At least one-grade reduction in Midface volume deficit scale (MFVDS) | Baseline, 4 weeks after injection | At least a one-grade reduction from baseline in Midface volume deficit scale (MFVDS), as assessed by an independent physician based on photographs, where 0 represents no volume deficit and 5 represents severe volume deficit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depth of the right and left nasolabial folds | 4,12, and 24 weeks after injection | Depth of the right and left nasolabial folds, measured using standard frontal facial photographs taken with the Visioface device and analyzed via CSI software |
| Surface area of the right and left nasolabial folds | 4,12, and 24 weeks after injection | Surface area of the right and left nasolabial folds, measured using standard frontal facial photographs taken with the Visioface device and analyzed via CSI software |
| Volume of the right and left nasolabial folds | 4,12, and 24 weeks after injection | Volume of the right and left nasolabial folds, measured using standard frontal facial photographs taken with the Visioface device and analyzed via CSI software |
| At least a one-grade reduction in Midface volume deficit scale (MFVDS) | Baseline, 12 and 24 weeks after injection | At least a one-grade reduction from baseline in Midface volume deficit scale (MFVDS) as assessed by an independent physician based on photographs, where 0 represents no volume deficit and 5 represents severe volume deficit |
| Participants satisfaction | at 4, 12, and 24 weeks after injection | Participants' satisfaction assessed using the Visual Analogue Scale (VAS) from 0 to 10, where 0 represents complete dissatisfaction and 10 represents complete satisfaction |
| Assessment of midface area improvement | at 4, 12, and 24 weeks after the injection | Assessment of midface area improvement, based on the Global Aesthetic Improvement Scale (GAIS) as judged by the investigator compared to baseline, where 0 means the condition has been worsened and 4 represents excellent improvement |
| Safety assessment by evaluation of adverse events (AEs) | Immediately after injection; 4, 12, and 24 weeks after injection | All observed or reported adverse events immediately after injection, as well as 4, 12, and 24 weeks after injection, should be mentioned along with the severity grade (mild = 1, moderate = 2, and severe = 3). |
| Pain severity during injection | Intervention (day 0) | evaluated using the Visual Analogue Scale (VAS) from 0 to 10, where 0 indicates no pain at all and 10 indicates the maximum imaginable pain |
Countries
Iran
Outcome results
None listed